Cytosurge and Lexogen Partner to Advance Live-Cell Sequencing
15 oct. 2024 09h00 HE
|
Cytosurge AG; Lexogen GmbH
Cytosurge and Lexogen partner to advance Live-seq, integrating FluidFM® and LUTHOR HD to enable scalable, live-cell transcriptomics with high sensitivity.
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 08h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 02h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.